Conjugating a tumor-penetrating cyclic peptide (iRGD) to a PROTAC drug improved its water solubility, tumor targeting, and tissue penetration, enhancing breast cancer treatment in animal models and patient-derived organoids.
Enhanced tumor penetrationThe iRGD peptide conjugation enabled the PROTAC to penetrate deep into breast cancer tissue rather than remaining at the tumor periphery, addressing a critical limitation of current PROTAC therapies.
What the researchers found
The iRGD-PROTAC conjugate (iPR) was created by linking the tumor-penetrating cyclic peptide iRGD (CRGDK/RGPD/EC) to a BRD4-targeting PROTAC through a glutathione (GSH)-responsive linker that releases the active drug inside tumor cells.
Compared to the unconjugated PROTAC, the iRGD-PROTAC conjugate showed enhanced water solubility, improved tumor-targeting capability, and deeper penetration within breast cancer tissues. These improvements translated to increased anti-breast cancer efficacy in both animal models and patient-derived organoids, validating the concept that peptide-guided delivery can overcome key limitations of PROTAC-based cancer therapies.
Why it matters
PROTACs represent one of the most exciting advances in cancer drug development, but their clinical potential has been limited by poor drug-like properties — especially difficulty reaching tumor cells deep within solid tumors. By using a tumor-penetrating peptide as a delivery vehicle, this study addresses a major bottleneck in PROTAC therapeutics and demonstrates a modular strategy that could potentially be applied to PROTACs targeting many different cancer-driving proteins.
How the study worked
The researchers designed and synthesized an iRGD-PROTAC conjugate using a GSH-responsive cleavable linker. They evaluated water solubility, tumor-targeting ability, and tissue penetration through in vitro and in vivo experiments. Anti-cancer efficacy was tested in breast cancer animal models and patient-derived organoids (3D tumor tissue cultures grown from patient samples). The BRD4 PROTAC component was chosen as a proof-of-concept target for protein degradation.
What this study cannot tell us
This is a proof-of-concept study targeting only one protein (BRD4) in breast cancer. The approach needs to be validated with other PROTAC targets and cancer types. While patient-derived organoids provide better translational relevance than cell lines alone, they still differ from tumors in patients. Long-term toxicity, pharmacokinetics, and the stability of the GSH-responsive linker in circulation were not fully characterized in the abstract. Human clinical trials would be needed to confirm therapeutic benefit.
How to read the evidence
This is a preclinical proof-of-concept study with validation in both animal models and patient-derived organoids, representing a higher standard than cell line-only studies. However, it targets a single protein in one cancer type and lacks human clinical data, placing it at a moderate preclinical evidence level.
When this study was published
Published in 2023, this is a recent study in the rapidly advancing fields of PROTAC therapeutics and peptide-guided drug delivery. Both areas are seeing intense research activity and clinical translation efforts.
The bigger picture
This study sits at the intersection of two cutting-edge drug development fields: PROTACs (targeted protein degradation) and peptide-guided drug delivery. The iRGD peptide has been studied extensively for its ability to penetrate tumors by binding to integrins on tumor blood vessels and then activating a transcytosis pathway. Combining this peptide navigation system with PROTAC technology creates a more targeted approach to cancer treatment that could reduce side effects while improving efficacy against solid tumors.
Questions still open
- Can the iRGD-PROTAC conjugation strategy be generalized to PROTACs targeting other cancer-driving proteins beyond BRD4?
- How does the GSH-responsive linker perform in terms of stability during circulation and selective release within tumors?
- Would this approach work in harder-to-penetrate solid tumors like pancreatic or brain cancers?
Common questions
What is a PROTAC and how does it kill cancer cells?
What is the iRGD peptide and why does it help?
Read the original research
Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
Journal of medicinal chemistry, 66(24), 16828-16842
Citation
He, Shipeng; Fang, Yuxin; Wu, Minghao; Zhang, Peifeng; Gao, Fei; Hu, Honggang; Sheng, Chunquan; Dong, Guoqiang. (2023). Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.. Journal of medicinal chemistry, 66(24), 16828-16842. https://doi.org/10.1021/acs.jmedchem.3c01539